Trends in Incidence and Mortality of Kidney Cancer in a Northern Italian Province: An Update to 2020

The aim of this study was to examine the incidence and mortality trends for tumors and cardiovascular disease (CVD) in a province of northern Italy. The study included kidney cancers recorded in the period 1996–2020, divided by sex, age, year of incidence and years from diagnosis. The standardized i...

Full description

Bibliographic Details
Main Authors: Lucia Mangone, Francesco Marinelli, Luigi Tarantini, Cristina Masini, Alessandro Navazio, Stefania Di Girolamo, Isabella Bisceglia, Carmine Pinto
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Biology
Subjects:
Online Access:https://www.mdpi.com/2079-7737/11/7/1048
Description
Summary:The aim of this study was to examine the incidence and mortality trends for tumors and cardiovascular disease (CVD) in a province of northern Italy. The study included kidney cancers recorded in the period 1996–2020, divided by sex, age, year of incidence and years from diagnosis. The standardized incidence rate was calculated using the European population, and the Annual Percent Change (APC) was reported. In total, 2331 patients with kidney cancers were identified, mainly males (1504 cases) aged 60–79 years (1240 cases). There were 1257 deaths; there were no differences according sex but there were differences according to age (12.1% among younger adults and 80.4% among 80+). The incidence rate increased in males between 1996 and 2011 (APC = 2.3), while the mortality rate decreased in both males (APC = −3.3%) and females (APC = −4.5%). Comparing the same periods, kidney cancer-specific mortality decreased from 81.8% to 43.7%, while in the same period there was an increasing trend for CVD mortality. Moreover, the risk of CVD mortality increased as we moved away from the diagnosis (from 6.2% to 27.5%, <i>p</i> < 0.01). The same trend was observed for other causes of death (from 12.6% to 32.1%, <i>p</i> < 0.01). Thus, a multidisciplinary approach seems necessary during the follow-up and treatments of patients with kidney cancer.
ISSN:2079-7737